These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35795617)

  • 1. Diagnostic Value of Magnetic Resonance Susceptibility-Weighted Imaging Scanning in Different Types of Early Prostate Cancer.
    Gao R; Liu J; Zhu H
    Scanning; 2022; 2022():4884646. PubMed ID: 35795617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
    Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
    [No Abstract]   [Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 6. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
    Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
    Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.
    Sun H; Du F; Liu Y; Li Q; Liu X; Wang T
    Front Oncol; 2022; 12():925186. PubMed ID: 36578948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of relaxation time quantitative technique from synthetic magnetic resonance imaging in the diagnosis and invasion assessment of prostate cancer].
    Song N; Wang T; Zhang D; Wang Z; Zhang SR; Yu J; Cai L; Ma AL; Zhang Q; Chen ZQ
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1093-1099. PubMed ID: 35436808
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
    Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
    Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
    Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
    Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
    Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
    JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
    Li K; Luan Q; Zheng J; Li R; Li L; Sun Y; Liu D
    Anticancer Res; 2023 Jan; 43(1):441-447. PubMed ID: 36585192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different population-averaged arterial-input-functions in dynamic contrast-enhanced MRI of the prostate: Effects on pharmacokinetic parameters and their diagnostic performance.
    Othman AE; Falkner F; Kessler DE; Martirosian P; Weiss J; Kruck S; Kaufmann S; Grimm R; Kramer U; Nikolaou K; Notohamiprodjo M
    Magn Reson Imaging; 2016 May; 34(4):496-501. PubMed ID: 26708031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer.
    Ziayee F; Mueller-Lutz A; Gross J; Ullrich T; Quentin M; Arsov C; Antoch G; Wittsack HJ; Schimmöller L
    Diagn Interv Radiol; 2022 Mar; 28(2):108-114. PubMed ID: 35548894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.